COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions by Sofia Ramiro, Robert B M Landewé, Rémy L M Mostard

Get full text

Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time by Niels W. Boone, Alexandre Sepriano, Paul-Hugo van der Kuy, Rob Janknegt, Ralph Peeters, Robert B. M. Landewé

Get full text

Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis by Sytske Anne Bergstra, Cornelia F. Allaart, Rosaline van den Berg, Arvind Chopra, Nimmisha Govind, Tom W. J. Huizinga, Robert B. M. Landewe

Get full text

Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning by Sytske Anne Bergstra, Otto Olivas, Gülşah Akdemir, Naghmeh Riyazi, Gerard Collée, Johannes H. L. M. van Groenendael, Robert B. M. Landewé, Cornelia F. Allaart

Get full text

Ultrasound-guided lymph node biopsy sampling to study the immunopathogenesis of rheumatoid arthritis: a well-tolerated valuable research tool by Renée H. Fiechter, Janne W. Bolt, Marleen G. H. van de Sande, Caroline J. Aalbers, Robert B. M. Landewé, Mario Maas, Sander W. Tas, Lisa G. M. van Baarsen

Get full text

The effect of rituximab on patient reported outcomes in the preclinical phase of rheumatoid arthritis: 2 year data from the PRAIRI study by Ronald F van Vollenhoven, Danielle M Gerlag, Karen I Maijer, Sander W Tas, Niek de Vries, Paul P Tak, Robert B M Landewé, Lisa G M van Baarsen, Giulia Frazzei, Sophie H M Cramer

Get full text

Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study by Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha

Get full text

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies by Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates

Get full text

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study by Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha

Get full text

Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis by Atul Deodhar, Servet Akar, Jeffrey R. Curtis, Bassel El-Zorkany, Marina Magrey, Cunshan Wang, Joseph Wu, Solomon B. Makgoeng, Ivana Vranic, Sujatha Menon, Dona L. Fleishaker, Annette M. Diehl, Lara Fallon, Arne Yndestad, Robert B. M. Landewé

Get full text

Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment by Marjan Ghiti Moghadam, Femke B. G. Lamers-Karnebeek, Harald E. Vonkeman, Peter M. ten Klooster, Janneke Tekstra, Barbara van Schaeybroeck, Ruth Klaasen, Marieke van Onna, Hein J. Bernelot Moens, Henk Visser, Annemarie M. Schilder, Marc R. Kok, Robert B. M. Landewé, Piet L. C. M. van Riel, Mart A. F. J. van de Laar, Tim L. Jansen, on behalf of the Dutch National POET Collaboration

Get full text